Association between preoperative biologic use and surgical morbidity in patients with Crohn’s disease

Keyphrases

• Risk Factors 100%
• Crohn's Disease 100%
• Surgical Morbidity 100%
• Smoking Status 66%
• Preoperative Treatment 66%
• Current Smoking 66%
• Abdominoperineal Resection 66%
• Incisional SSI 66%
• Before Surgery 33%
• Confounding Factors 33%
• Number of Patients 33%
• Further Analysis 33%
• Surgical Site Infection 33%
• Surgically Treated 33%
• Selection Bias 33%
• Ustekinumab 33%
• Possible Risk Factors 33%
• Blood Sugar 33%
• Surveillance Data 33%
• Surgical Mortality 33%
• Urgent Surgery 33%
• Penetrating Disease 33%
• American Society of Anesthesiologists Score 33%
• Anti-TNF Agents 33%

Nursing and Health Professions

• Patient with Crohn's Disease 100%
• Preoperative Treatment 66%
• Biological Product 66%
• Rectum Abdominoperineal Resection 66%
• Disease 33%
• Confounding Factor 33%
• Glucose Blood Level 33%
• Surgical Infection 33%
• Surgical Mortality 33%
• Tumor Necrosis Factor Inhibitor 33%
• Ustekinumab 33%
• Anesthesist 33%

Medicine and Dentistry

• Patient with Crohn's Disease 100%
• Preoperative Treatment 66%
• Biological Product 66%
• Abdominoperineal Resection 66%
• Disease 33%
• Surgical Mortality 33%
• TNF Inhibitor 33%
• Surgical Infection 33%
• Selection Bias 33%
• Anesthesiologist 33%
• Ustekinumab 33%